camonsertib
camonsertib: sourced relationships with 1 company · 6 clinical trials tracked.
camonsertib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could camonsertib → RPTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Repare Therapeutics Inc. (RPTX) Solid Tumor; Chronic Lymphocytic Leukemia; Advanced Cancer | Phase 2 |
Clinical Trial Registry Records (6)
A Phase II Study of RP-6306 in Patients With Advanced Cancer
Primary endpoint: Response rate of RP-6306 in patients with selected cancers receiving standard agent
RP-3500 (ATRi) + External Beam Radiotherapy (EBRT) for the Palliative Treatment of Metastatic Disease
Primary endpoint: Phase I - Safety and Tolerability of RP-3500 in combination with radiation therapy
A Phase Ib/II Trial of Combination RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
Primary endpoint: Maximum Tolerated Dose (MTD) of Camonsertib (RP-3500) in Combination With Olaparib
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)
Primary endpoint: Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Primary endpoint: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Primary endpoint: Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above
Frequently asked questions
Which companies have sourced relationships with camonsertib?
camonsertib has dated SEC/FDA relationship records for Repare Therapeutics Inc..
How many clinical trials involve camonsertib?
BioSniper tracks 6 clinical trials involving camonsertib.